Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Merck it is followed byJohnson & Johnson’s leadershipand reported the expected financial hittariffsApplied by Trump management.
April 24, the call, the executors said they expect the costs related to $ 200 million in tariffs in 2025. Merck lowered $ 8.88 per share – $ 8.82 – $ 8.82-9.03 lowered $ 9.03 to $ 9.03.
News A week later, J & J leaders come after waiting for $ 400 million in tariff induction expenditures in 2025.
Robert Davis, the chairman of Merck and the director of the Mercy, first of all, the impact of the existing tariffs between the United States and China, the existing tariffs between Canada and Mexico, he said.
AlthoughthreatDavis investigating the national security effects of Pharmacey’s imports of Pharmacey tariffs on April 14, investigating the impact of pharmaceutical imports.
“In relation to potential tariffs for drug medicines, global supply chain and current inventory levels in the United States, putting us in good condition to manage our current inventory levels.
During the income, when Merck asked how to prepare for potential drug tariffs, the company said, changing the priorities of foreign production, foreign production and domestic production, including the ways “placement”.
Merck produced $ 12 billion in US since 2018 and plans to invest $ 9 billion in 2028.
Enlarge It turned out.Merck is not the only lead to emphasizing US investments.
In March, J & J leaders said the company plans to invest $ 55 billion in US production in the next four years. And in February, Eli lilli Executors said the company will invest at least $ 27 billion to open a plant in four new US plants in the next five years.
All three pharmacies have said that 2018 tax cutting and business acts have reduced the internal tax rate for pharmaceutical companies.
“It is a very effective tool for the power of tax policy, not fares, but also in the United States and the pharmacy,” – Joaquin Duato Duato during the company’s profit.
A fast rundown.Worldwide sales for the 2025 Q1 2025 have fallen by $ 15.5 billion, Q1 in 2024.
Despite the 2025 Earnings Reducing Earnings, the company is expected to decline in $ 65.1 billion in the world this year for $ 65.6 billion.
Merck, Daina Graybosch, which has a period of $ 4.2 billion from Daina Graybosch to $ 4.2 billion in 2028, increased by $ 4.2 billion to $ 4.2 billion. The expectations of partners.
This report was Was first published by Health brew.
This story was first displayed Fortune.com
